1. Home
  2. DCOMG vs IMTX Comparison

DCOMG vs IMTX Comparison

Compare DCOMG & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DCOMG
    SELLHOLDBUYas of 2024 years ago
  • IMTX
    SELLHOLDBUYas of 18 hours ago
  • Stock Information
  • Founded
  • DCOMG N/A
  • IMTX N/A
  • Country
  • DCOMG
  • IMTX Germany
  • Employees
  • DCOMG N/A
  • IMTX N/A
  • Industry
  • DCOMG
  • IMTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • DCOMG
  • IMTX Health Care
  • Exchange
  • DCOMG NYSE
  • IMTX Nasdaq
  • Market Cap
  • DCOMG N/A
  • IMTX 466.8M
  • IPO Year
  • DCOMG N/A
  • IMTX N/A
  • Fundamental
  • Price
  • DCOMG $25.13
  • IMTX $3.50
  • Analyst Decision
  • DCOMG
  • IMTX Strong Buy
  • Analyst Count
  • DCOMG 0
  • IMTX 4
  • Target Price
  • DCOMG N/A
  • IMTX $16.67
  • AVG Volume (30 Days)
  • DCOMG N/A
  • IMTX 770.5K
  • Earning Date
  • DCOMG N/A
  • IMTX 05-13-2025
  • Dividend Yield
  • DCOMG N/A
  • IMTX N/A
  • EPS Growth
  • DCOMG N/A
  • IMTX N/A
  • EPS
  • DCOMG N/A
  • IMTX 0.14
  • Revenue
  • DCOMG N/A
  • IMTX $161,336,577.00
  • Revenue This Year
  • DCOMG N/A
  • IMTX N/A
  • Revenue Next Year
  • DCOMG N/A
  • IMTX $2.63
  • P/E Ratio
  • DCOMG N/A
  • IMTX $26.49
  • Revenue Growth
  • DCOMG N/A
  • IMTX 188.60
  • 52 Week Low
  • DCOMG N/A
  • IMTX $3.39
  • 52 Week High
  • DCOMG N/A
  • IMTX $13.77
  • Technical
  • Relative Strength Index (RSI)
  • DCOMG N/A
  • IMTX 29.13
  • Support Level
  • DCOMG N/A
  • IMTX $4.46
  • Resistance Level
  • DCOMG N/A
  • IMTX $4.26
  • Average True Range (ATR)
  • DCOMG 0.00
  • IMTX 0.40
  • MACD
  • DCOMG 0.00
  • IMTX -0.11
  • Stochastic Oscillator
  • DCOMG 0.00
  • IMTX 4.91

Stock Price Comparison Chart: DCOMG vs IMTX

DCOMG
IMTX
JulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025April0246810121416182022242628DCOMG VS IMTX

About IMTX Immatics N.V.

Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.

Share on Social Networks:

0

By browsing this website, you accept our Privacy Policy & Terms of Use